Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies by Sorich, Michael J & Coory, Michael
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
‘This is the peer reviewed version of the following 
article: Sorich, M. J., & Coory, M. (2013, September 10). 
Interpreting the clinical utility of a pharmacogenomic 
marker based on observational association studies. The 
Pharmacogenomics Journal. Springer Nature. https://
doi.org/10.1038/tpj.2013.35 
which has been published in final form at 
DOI:
http://dx.doi.org/10.1038/tpj.2013.35 
This article may be used for non-commercial purposes 
in accordance with Springer Nature Terms and 
Conditions for self-archiving.
doi: 10.1038/tpj.2013.35  
Interpreting the clinical utility of a pharmacogenomic marker based on observational association 
studies 
Michael J Sorich1, Michael Coory2 
1School of Pharmacy and Medical Sciences, University of South Australia, Adelaide SA 5001, Australia 
Michael J Sorich  
2Murdoch Childrens Research Institute, Melbourne VIC 3052, Australia Michael Coory  
 
Correspondence to:  
Michael Sorich  
Email: michael.sorich@flinders.edu.au 
Tel: +61 8 82046682 
Fax: +61 8 8302 2389  
 
Funding: Financial support for this study was provided by a grant from the National Heart 
Foundation of Australia [grant number G11A5902] and the National Health and Medical Research 
Council of Australia [grant number 1028492]. 
Conflict of interest: The authors declare no conflict of interest.  
Abstract 
It is increasingly recognized that the clinical utility of a pharmacogenomic marker is a fundamental 
characteristic influencing the likelihood of successful clinical translation. Although appropriately 
designed and executed randomized controlled trials generally provide the most valid evidence for 
the clinical utility of a pharmacogenomic marker, such evidence may not always be available. 
Observational pharmacogenomic association studies are a common form of evidence available, but 
the assessment of clinical utility based on such evidence is often not straightforward. This paper 
aims to provide insight into this issue using a range of illustrative examples.  
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One of the main goals of pharmacogenomics is to improve medical decision making through better 
prediction of treatment response (safety and effectiveness).1, 2 It is increasingly recognized that 
clinical translation of a pharmacogenomic marker is strongly dependent on its clinical utility – that is, 
whether routine testing improves patients’ outcomes.3, 4 Towards this end, it is important to 
understand whether treatment response differs between pharmacogenomic subgroups. Cost-
effectiveness, another important characteristic influencing clinical translation, is also dependent on 
the treatment response estimated for pharmacogenomic subgroups.5-7 Observational association 
studies are a common form of evidence for pharmacogenomic markers. However, it is often not well 
appreciated that interpreting the clinical utility (and consequently the cost-effectiveness) of a 
pharmacogenomic marker is not straightforward based on such evidence.1 This paper therefore aims 
to provide insight into this issue using a range of illustrative examples.  
Types of pharmacogenomic markers and study designs 
There are two major ways in which a pharmacogenomic marker may affect the risk of a clinical or 
surrogate outcome. As there is currently no standard terminology we use the terms ‘prognostic’ and 
‘predictive’ which are commonly used in the oncology literature.8  
Using this standard framework, a marker is ‘prognostic’ if it influences the natural course/history of 
a disease and thus ‘prognostic’ markers generally affect the risk of outcomes irrespective of the 
intervention. Thus, a purely ‘prognostic’ marker will not influence treatment response - defined in 
this context as the relative risk (RR) or relative risk reduction (RRR) associated with treatment. For 
example, blood lipid levels predict the risk of cardiovascular outcomes, but are not generally though 
to influence the RRR associated with statin therapy.9Thus, lipid levels would be considered 
‘prognostic’ for cardiovascular outcomes but not ‘predictive’ of statin effect on cardiovascular 
outcomes. It is important to note that although a ‘prognostic’ marker does not influence RRR, it can 
influence the absolute risk reduction (ARR) and the number need to treat (NNT). For example, 
individuals with higher lipid levels receive the same RRR with statin treatment as individuals with 
lower lipid levels, but the will have a greater ARR as a consequence of their greater underlying 
cardiovascular risk.9  
‘Predictive’ markers are specific to a drug or drug class and identify subgroups for which the 
treatment response (RR or RRR) differs. The most useful examples of ‘predictive’ markers are able to 
separate a subgroup with substantial treatment response from a subgroup with no treatment 
response (RRR=0). The ability of a ‘predictive’ marker to potentially identify a group with no 
treatment response (as compared to the ability of a ‘prognostic’ marker to identify a group with 
reduced response) is a key reason why ‘predictive’ markers are particularly sought after  It is 
important to note that some pharmacogenomic markers have a mix of both ‘prognostic’ and 
‘predictive’ effects – that is, affect both the natural course of the disease and treatment response. 
The complexities associated with combined ‘prognostic’ and ‘predictive’ effects will be explored in 
more detail later. 
In general, an appropriately designed and executed randomized controlled trial (RCT) will provide 
the highest quality evidence of the clinical utility and cost-effectiveness of a pharmacogenomic 
marker.10-12 Such a study may provide estimates of the treatment response for each 
pharmacogenomic subgroup and assess whether there is differential treatment response between 
pharmacogenomic subgroups. To do so the RCT would need to include the appropriate groups of 
participants. For a simple example in which the pharmacogenomic marker has only two possible 
values (e.g. positive and negative) and there are only two relevant treatment options (e.g. treatment 
vs. no treatment) then four groups would ideally be studied (i.e. treatment + positive marker, no 
treatment + positive marker, treatment + negative marker, no treatment + negative marker).1  
Nonetheless, a common approach for initial assessment of the value of a pharmacogenomic marker 
is an observational association study. These are predominantly cohort or case-control studies which 
assess the correlation between the pharmacogenomic marker and an outcome of interest. 
Importantly, these studies generally include only individuals on a specific treatment – that is, only 
two of the four patient groups are studied. Because two of the four groups are missing, it is not 
simple to interpret the clinical utility and cost-effectiveness of the marker without further 
information/assumptions concerning the ‘prognostic’ and ‘predictive’ character of the marker. 
Illustrative example 
Assume that a particular treatment is the standard of care for reducing the risk of an adverse clinical 
outcome and that a mutation in a particular gene is proposed as a pharmacogenomic marker of the 
treatment’s effectiveness. Individuals are classified into two subgroups depending on whether they 
have or do not have the mutation. A cohort study is undertaken which enrolls individuals that are 
using the treatment. The results indicate that individuals with the gene mutation have double the 
risk of the clinical outcome (10% risk vs 5% risk for individuals without the gene mutation). Does this 
pharmacogenomic marker have clinical utility? If so, how should a test for the pharmacogenomic 
marker be used to guide selection of therapy? 
As indicated previously this pharmacogenomic association study only provides information on two of 
the four groups. Figure 1 displays the clinical outcome results for patients who are on the treatment 
(right hand side of each figure) with a range of plausible scenarios for the clinical outcomes of 
patients who are not on the treatment (the left hand side of each figure). Lines that join the clinical 
outcomes of patients with and without treatment highlight the treatment response (ability to reduce 
risk) for each pharmacogenomic subgroup.  
Assuming a purely ‘predictive’ marker 
If it is assumed that the gene mutation is a ‘predictive’ marker with no ‘prognostic’ effects, the 
difference in the risk of the clinical outcome identified in the association study must be due to 
differential treatment response. As the gene mutation is not ‘prognostic’, the mutation only 
influences clinical outcomes for individuals who are on the treatment. Figure 1a displays an example 
in which individuals with the mutation are assumed to receive no benefit (RRR = 0%). Under these 
assumptions, there would be clinical utility (i.e., health gain) in screening for the gene mutation as 
the adverse effects and the cost of unnecessary therapy would be avoided with no loss of 
therapeutic benefit. Unless the mutation is very rare or the pharmacogenomic test is very expensive 
this scenario is also likely to be cost-effective. 
However, alternative scenarios for a purely ‘predicative’ marker are also plausible. Figure 1b displays 
an example in which individuals with the mutation do receive benefit from treatment (RRR = 20%) 
but it is substantially less than individuals without the mutation (RRR = 60%). In this case, the clinical 
utility of screening for the gene mutation is not straightforward and may depend on whether the 
treatment has substantial adverse effects that may outweight the therapeutic effect for individuals 
with the mutation or whether there is an alternative treatment available that has a superior 
therapeutic effect for the individuals with the mutation. The clinical use of the pharmacogenomic 
marker may also be potentially justified on the basis of cost-effectiveness ifthe modest benefit for 
individuals with a mutation is not considered to be an effective use of finite healthcare resources. 
This is most likely to be relevant for high-cost treatments. .  
Assuming a purely ‘prognostic’ marker 
It may also be plausible that the gene mutation is a purely ‘prognostic’ marker. In such a case, the 
mutation only influences the disease; and has no effect on the treatment RRR. As the marker is 
‘prognostic’ individuals with and without the mutation will have different risk of the clinical outcome 
even if they are not on the treatment. Figure 1c demonstrates a ‘prognostic’ marker for which the 
treatment response is the same (RRR of 30%) irrespective of whether the individual has the 
mutation. In this case, individuals with the mutation will be at higher risk without treatment and 
consequently will receive the greatest ARR from treatment. Importantly, although there are 
similarities with the prior example (i.e. both group receive some benefit from treatment) the 
subgroup that receives the greater ARR is reversed (see Figure 1b and 1c). 
Examples with RCT based evidence 
One of the best examples of a ‘predictive’ pharmacogenomic marker routinely used in clinical 
practice is KRAS genotype to guide use of anti-EGFR monoclonal antibodies in advanced colorectal 
cancer. Figure 2a summarises the results of a pivotal RCT in which individuals with a KRAS mutation 
demonstrated no survival benefit from treatment.13 BRAF mutations have also been studied for 
guiding the same therapy, but current evidence suggests that BRAF mutations are ‘prognostic’ rather 
than ‘predictive’ (Figure 2b).14 As both BRAF subgroups appear to benefit from treatment this 
marker is not commonly used to guide treatment of anti-EGFR antibodies. However, if evidence 
were only available from on-treatment association studies (see right hand side of Figures 2a and 2b) 
it would be difficult to distinguish the clinical utility of KRAS and BRAF mutations in this setting. It is 
also worth noting that although BRAF mutations are not ‘predictive’ for this treatment and cancer, 
they are thought to be ‘predictive’ for vemurafenib therapy in advanced melanoma.15 That is, the 
prognostic/predictive characteristics of the same pharmacogenomic marker may differ between 
settings (e.g. different disease types and treatments).  
The Oncotype DX breast cancer test, which is based on the expression of 21 genes in a tumor 
sample, is another test used in clinical practice. An RCT has suggested that the Oncotype DX breast 
cancer test has both ‘prognostic’ and ‘predictive’ characteristics (Figure 3a).16 That is, the test score 
provides insight into both the underlying risk of cancer recurrence and the ability of chemotherapy 
to prevent cancer recurrence.16 Of note, if the marker has both ‘prognostic’ and ‘predictive’ 
characteristics the results of a pharmacogenomic association study can be particularly difficult to 
interpret. For example, if an association study had been undertaken including only individuals using 
chemotherapy little difference in the risk of cancer recurrence would be expected between 
individuals with high and low recurrence scores (see right hand side of Figure 2c). Thus, an 
association study that does not find a difference in event risk between pharmacogenomic groups 
does not necessarily mean that the marker is without clinical utility. 
Although there are few examples outside of oncology of ‘predictive’ markers that currently have a 
strong evidence base and clear clinical utility, examples from other therapeutic areas can still 
provide insight into the difficulty of interpreting clinical utility from association studies. For instance, 
many studies have assessed whether cytochrome P450 (CYP) 2C19 genotype influences adverse 
cardiovascular outcomes for individuals on the anti-platelet agent clopidogrel.17-19 Figure 3a displays 
the results from an RCT substudy comparing clopidogrel to an alternative anti-platelet agent, 
ticagrelor.20 Although it does provide modest support for a ‘predictive’ effect it also suggests that 
ticagrelor is likely to have benefit over clopidogrel irrespective of CYP2C19 genotype. This insight 
into the expected clinical utility of assessing CYP2C19 genotype is difficult to gain from the large 
number of published association studies.21 
KIF6 genotype has been suggested to be associated with both the cardiovascular risk and the 
response to statin drugs. Although the evidence supporting the clinical utility22 and cost-
effectiveness23 of KIF6 genotyping is controversial the example is still useful for illustrative purposes. 
Figure 3b displays the results of a study in which the subgroup with a KIF6 mutation demonstrated a 
greater relative reduction in coronary events due to statin therapy (‘predictive’ effect), but also a 
higher general risk of coronary events (‘prognostic’ effect).24 A meta-analysis of observational 
studies subsequently was not able to identify a significant association between KIF6 genotype and 
coronary artery disease which suggested there was no ‘prognostic’ effect.25 However, it has been 
argued that if KIF6 genotype is truly predictive of statin treatment response then little difference in 
risk would be expected between KIF6 genotype subgroups if the majority of individuals in the 
association study were using statin therapy (see right hand side of Figure 3b).26  
Evidence-based pharmacogenomics: balancing quality and feasibility  
There is a growing awareness of the evidence dilemma with respect to the clinical translation of 
pharmacogenomics.27 In the era of evidence-based medicine there is a clear interest in developing 
the highest quality evidence to guide whether a pharmacogenomic test should be integrated into 
standard medical practice. Decisions on whether a drug should be used in clinical practice are 
typically based on evidence from one or more RCTs and thus it is reasonable to question whether 
similar levels of evidence should be required for pharmacogenomic markers which guide drug and 
dose selection. The major caveat is the feasibility of undertaking prospective RCTs to support each 
pharmacogenomic marker. The expense of undertaking adequately powered RCTs of clinical 
outcomes for new drugs may be justifiable for the pharmaceutical industry due to the substantial 
potential return on investment for drugs. However, a similar return on investment is not anticipated 
for pharmacogenomic tests and public funding is unlikely to be sufficient to support such research. 
This is likely to be particularly problematic for pharmacogenomic markers that are rare (e.g rare 
genetic variants) and/or predict rare clinical outcomes (e.g. severe adverse drug reactions28). To date 
there have been very few examples of RCTs specifically designed to assess the clinical utility of a 
pharmacogenomic marker that are adequately powered to detect relevant clinical outcomes. 
Prominent examples are the RCTs of genotype-guided warfarin dosing (COAG29 and EUPACT30) and 
expression profiles to guide use of chemotherapy in early breast cancer (TAILORx31 and MINDACT32).      
 
A practical option for developing high quality evidence of clinical utility may be the retrospective 
analysis of conventional RCTs that have archived biological samples (sometimes also called a genetic 
or genomic substudy of an RCT). This approach allows evidence based on randomized treatment 
allocation to be developed relatively quickly and inexpensively.10-12 The examples described above 
for KRAS, Oncotype DX, CYP2C19, and KIF6 were all based on evidence developed from secondary 
analysis of a conventional RCT. The validity of such secondary analyses depends on the manner in 
which the study is undertaken. In particular, it is important that a hypothesis driven statistical 
analysis plan is prespecified, and that a large proportion of the RCT participants have biological 
samples available for analysis.11, 12 It is likely that secondary analysis of existing RCTs will often be 
underpowered to detect ‘predictive’ markers and this will particularly be the case for rare clinical 
outcomes and rare pharmacogenomic markers. Secondary analysis of RCT data will not always be 
possible. For example, for older drugs the pivotal RCTs may have taken place at a time when 
biological samples were not archived for future use. Additionally, RCTs may not be available with the 
appropriate treatment comparison for the pharmacogenomic marker. As major RCTs more 
commonly compare different drugs rather than different doses of a drug, secondary analysis of RCTs 
is likely to be most useful to provide evidence for pharmacogenomic markers that guide choice of 
drug rather than choice of dose. Consequently a prospective RCT will often be the only option if RCT 
evidence is required to confirm that genotype-guided dose adjustment improves treatment 
outcomes.29, 30 
 
If RCT based data is unavailable additional observation studies may be of some value to better 
understand the likely clinical utility. Specifically, observational studies of the same 
pharmacogenomic marker in a similar patient cohort that are not on the treatment of interest may 
help provide support for whether the marker is likely to have ‘prognostic’ and/or ‘predictive’ effects. 
For example, if the pharmacogenomic marker is associated with a similar effect on the clinical 
outcome irrespective of whether the study participants are using or not using the treatment of 
interest then this provides some support to the hypothesis that the marker is predominantly 
‘prognostic’ (see Figure 1c). Conversely, if there is differential risk between pharmacogenomic 
marker subgroups only for studies in which individuals are using the treatment then this provides 
some support to the hypothesis that the marker is ‘predictive’ with respect to the treatment (see 
Figures 1a and 1b). It is also possible to quantitatively synthesize the observational evidence for the 
pharmacogenomic marker in order to indirectly estimate the treatment response within 
pharmacogenomic subgroups.33 This approach has been utilized to gain insight of both clinical utility 
and cost-effectiveness.18, 34, 35 However, it is important to be aware of the strong assumptions that 
are generally required for such modeling and hence there is a significant risk of bias associated with 
the indirect estimates.33 Finally, if the biology of the pharmacogenomic marker and the disease, and 
the pharmacokinetics and pharmacodynamics of the drug treatment are all well understood they 
may provide corroborative support of whether the marker is more likely to affect the disease 
process (prognostic) or the drug’s effect (predictive).  
Conclusion 
We provide here insight into the difficulties of interpreting clinical utility from pharmacogenomic 
observational studies of individuals using a specific treatment. Data from an RCT generally provides 
more valid and interpretable evidence for clinical utility and observational data is most useful in the 
context of prioritizing and building a case for acquiring RCT-based data.  Secondary analysis of 
existing conventional RCTs with archived biological samples is a practical approach for deriving RCT 
based evidence that may be possible for some but not all pharmacogenomic markers. For cases in 
which secondary analysis of existing RCTs is not possible prospective RCTs are an option but will 
often be impractical due to cost. There is clear need for innovative policy and methods for effectively 
progressing the clinical development/translation of pharmacogenomic markers for which 
observational evidence suggests potential clinical utility but there is little prospect of obtaining RCT-
based confirmatory evidence.  
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Figure 1: Interpretation of the clinical utility for a hypothetical pharmacogenomic marker based on 
an association study result assuming; (A) a purely ‘predictive’ marker which is able to identify a 
subgroup with no benefit from treatment, (B) a purely ‘predictive’ marker which is able to identify a 
subgroup with reduced benefit from treatment, and (C) a purely ‘prognostic’ marker. 
NNT: number needed to treat 
 
Figure 2. Examples of oncology pharmacogenomic markers; (A) KRAS mutations and third-line 
cetuximab therapy for colorectal cancer, (B) BRAF mutations and first-line cetuximab therapy for 
colorectal cancer, (C) Oncotype Dx breast cancer test and adjuvant chemotherapy. 
RS = recurrence score 
 
Figure 3. Examples of putative cardiovascular pharmacogenomic markers; (A) cytochrome P450 2C19 
genotype (loss-of-function allele) and clopidogrel therapy for individuals with acute coronary 
syndrome, and (B) KIF6 genotype for statin therapy. 
 
 
